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Objective: Despite evidence indicating a heightened incidence of psychological symptoms in 
coeliac disease (CD), the direct link between psychological factors and quality of life (QOL) has 
received little attention. The purpose of this paper was to compare the relative impacts of 
psychological symptoms and coping to the known negative impacts of gastrointestinal symptoms 
and adherence to the gluten free diet (GFD) on QOL.  
Methods: In study 1 (N = 390), participants completed measures of QOL, psychological 
symptoms, coping, several indices of symptom severity, and adherence. Correlations and 
regression analyses were used to determine the relationships between QOL and the measured 
variables. Study 2 (N = 189) replicated the findings using a validated measure of current 
gastrointestinal symptom severity and more a comprehensive measure of coping.  
Results: Across both studies, poorer QOL was correlated with a higher incidence of 
psychological and gastrointestinal symptoms, greater reliance on maladaptive coping strategies, 
and poorer GFD adherence. The relationship between psychological symptoms (particularly 
depression) and QOL persisted when controlling for past (study 1) and current (study 2) 
gastrointestinal symptom severity. Psychological symptoms and GFD adherence were more 
strongly related to reduced QOL than gastrointestinal symptoms.  
Conclusion: The negative impact of psychological symptoms on QOL and adherence suggests 
that management in CD should include the provision of psychological coping skills, as well as 
purely dietetic-based strategies to minimise gastrointestinal symptoms.      
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Coeliac disease (CD) is a chronic autoimmune disorder involving intolerance for dietary 
gluten (1). Consequently, treatment involves the removal of all gluten from the diet, and indeed 
the only available treatment is strict adherence to a lifelong gluten free diet (GFD) (1, 2). The 
clinical presentation of undiagnosed or untreated CD can include symptoms relating to the 
malabsorption of nutrients (e.g., iron/calcium deficiencies, fatigue, weight loss), as well as 
gastrointestinal symptoms resulting from damage to the small intestine (e.g., diarrhoea, 
cramping) (3, 4). The disease can manifest as classical (diarrhoea either with or without 
accompanying malabsorption symptoms), atypical (gastrointestinal symptoms are absent/not 
prominent; extra-intestinal symptoms often prompt diagnosis), or silent (no symptoms present) 
(4). If left untreated or poorly managed, CD has been linked to several long-term health 
complications including intestinal and bowel cancers, osteoporosis, and infertility (5). 
CD is a genetically mediated condition (6), and is estimated to affect approximately 1% 
of the population, making it the most prevalent autoimmune disorder in the world (7, 8). 
Serological prevalence rates do, however, differ between countries; for example, a recent 
international screening study found rates of 2.4% in Finland, while only 0.3% in Germany (9). 
Due to the varied presentation of CD it is estimated that up to 75% of cases remain undiagnosed 
(2, 10, 11). CD can develop at any age, although peaks in diagnosis have been observed in early 
childhood and the fourth and sixth-to-seventh decades of life (12). Consistent with most 
autoimmune disorders, CD is more common in females than males (ratio of 2-3:1), although the 
reason for this is not known (3, 7).  
Reduced quality of life (QOL) has been commonly observed in patients with CD 
compared to healthy control participants (13-18). Investigations have focused largely on 
demographic (e.g., gender, whereby females commonly report poorer QOL than males) (15, 19-
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21); medical (e.g., gastrointestinal symptoms, whereby more severe symptoms are associated 
with poorer QOL) (22-27); and dietary (e.g., GFD adherence, whereby poorer adherence is 
associated with poorer QOL; and perceived difficulty of adherence, which was also associated 
with poorer QOL) (23, 28-30) aspects of the disease. While these factors are important for QOL, 
one area that has received less attention is psychological symptoms and coping, despite higher 
rates of psychological symptoms within CD patients compared to the general population (16, 31-
36). Two studies found that increased depression and anxiety in CD were correlated with 
reduced QOL (16, 36), while a recent study found that emotion-oriented coping was negatively 
related to QOL (37). In the broader context, the link between QOL, psychopathology, and coping 
is well established (38-42), with depression representing the greatest threat to QOL across a 
range of populations (38). Together these findings suggest that psychological symptoms and 
coping are likely to be highly relevant to QOL in CD and warrant further attention.  
Further, research in a range of medical conditions has also demonstrated a direct link 
between the severity of gastrointestinal and psychological symptoms (43). For example, Walker 
and colleagues (44) found that patients suffering from inflammatory bowel disease with 
depression reported more severe gastrointestinal symptoms than those without depression. It was 
suggested that the presence of a psychological condition such as depression might serve to 
exacerbate the perception of physical symptoms (43, 44), both of which would then likely have a 
negative impact on QOL. Similarly, it was found that the majority of patients suffering from 
gastrointestinal disorders (including CD) presenting for treatment also showed symptoms of 
depression or elevated state anxiety (45).  
In CD, investigations into gastrointestinal and psychological symptoms and their relation 
to QOL have largely been conducted in isolation. In one study, Hauser and colleagues (24) 
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examined the impact of gastrointestinal symptoms and probable mental disorder (measured by a 
self-report questionnaire) on physical and psychological QOL and found that gastrointestinal 
symptoms but not psychological symptoms had a significant negative impact on physical QOL. 
The opposite pattern of results was observed for psychological QOL (24). This finding is not 
surprising given the degree of overlap between items designed to assess physical QOL and 
symptom severity, and psychological symptoms and psychological QOL. An important question 
that remains unanswered, however, is how gastrointestinal and psychological symptoms jointly 
impact QOL.  
The studies reported here therefore had two aims: (1) to determine the relative magnitude 
of the impact of psychological symptoms and coping on QOL in CD compared to the known 
negative impacts of female gender, inadequate GFD adherence, and increased gastrointestinal 
symptom severity; and (2) to examine the nature of the relationship between psychological 
symptoms and gastrointestinal symptom severity, and their joint impact on QOL. In the first 
study it was hypothesised that: 
• Poorer QOL would be associated with a higher incidence of psychological symptoms 
and increased reliance on maladaptive coping strategies, as well as poorer GFD 
adherence, female gender, and increased gastrointestinal symptom severity;  
• A relationship between gastrointestinal symptoms and psychological symptoms would 
exist, whereby individuals reporting more severe gastrointestinal symptoms would also 
exhibit more symptomatic psychological profiles; 
• Psychological symptoms would be more strongly associated with QOL than 
gastrointestinal symptoms;  
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• The negative impact of psychological symptoms on QOL would persist after controlling 
for gastrointestinal symptom severity.  
 
STUDY 1 METHOD 
Participants and procedure  
 A recruitment email was sent to a randomly selected sample (N = 2989; October, 2010) 
of members of the Coeliac Society of New South Wales who were identified via a database 
screen as meeting the following inclusion criteria: biopsy-confirmed CD, GFD duration >3 
months, aged >16 years. All data was collected and submitted anonymously online and took 
approximately 20 minutes. The data used in this study was originally collected with the aim of 
identifying the factors contributing to the intention-behaviour gap in GFD adherence and has 
been published elsewhere (46). It was, however, beyond the scope of that paper to also examine 
QOL.  
Measures 
 Participants completed demographics questions (age; gender; education; marital and 
employment status), and the following CD variables: age at diagnosis; symptom duration prior to 
diagnosis; duration of GFD; time to improvement after initiation of the GFD; family history of 
CD; and additional dietary allergies/intolerances (including dairy, egg, peanut, tree-nuts, 
shellfish, seafood, soy, and other) and medical comorbidities (free response). Gastrointestinal 
symptom severity was operationalised in two ways: current symptom severity represented the 
severity of symptoms when consuming gluten since initiation of the GFD, while consistent with 
a previous study (18), past symptom severity reflected the number of symptoms from a list of 
common CD symptoms that were endorsed as having been experienced prior to diagnosis.  
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 QOL was assessed using the overall QOL item (“How would you rate your quality of 
life?”) from the World Health Organisation Quality of Life Assessment (WHOQOL-BREF; 47). 
Scores range from 1-5, with higher scores indicating better QOL. The decision to use the single 
item rather than the entire scale to measure QOL was based on the significant and positive 
correlations observed between overall QOL and each of the domain scores in a previous sample 
of patients with CD (29). The Depression Anxiety Stress Scale (48, 49) was used to measure the 
negative emotional states of depression (e.g., “I felt downhearted and blue”), anxiety (“I felt I 
was close to panic”), and stress (“I tended to overreact to situations”). The scale contains 21 
items; subscale scores range from 0-42, and higher scores indicate more severe/frequent 
symptoms (49). The Eating Disorder Inventory-3 Eating Disorder Risk Scale (50) provided a 
measure of eating disorder symptomatology. The scale contains 25 items (e.g., “I eat when I am 
upset” and “I think about dieting”); raw scores range from 0-100, and higher scores indicate 
more severe eating disorder symptoms. The Coping Inventory for Stressful Situations (51) was 
used to measure adaptive (task-oriented; e.g., “Focus on the problem and see how I can solve it”) 
and maladaptive (emotion-oriented; e.g., “Blame myself for being too emotional about the 
situation”) coping. The scale contains 21 items measuring three distinct coping strategies (task-
oriented, emotion-oriented, and avoidance); however, the avoidance subscale was not included in 
analyses as it failed to correlate with any of the other variables of interest (46). Scores range 
from 7–35, with higher scores indicating more frequent use of the coping strategy (51). GFD 
adherence was measured using the Coeliac Dietary Adherence Test (52), which is a seven-item 
questionnaire shown to correlate highly with dietitian rated estimates of adherence (the gold 
standard). It contains items pertaining to three relevant domains: CD-related symptoms (2 items; 
e.g., “Have you been bothered by low energy levels in the past four weeks?”), self-efficacy (3 
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items; e.g., “I do not consider myself a failure”), and gluten avoidance habits (2 items; e.g., 
“How important to your heath are accidental gluten exposures?”). Scores range from 7-35, with 
higher scores indicating poorer adherence. The perceived difficulty of adhering to the GFD was 
assessed using the Perceived Behavioural Control scale of the Coeliac Disease Theory of 
Planned Behaviour Questionnaire (29). The scale contains four items (e.g., “How much personal 
control do you feel you have over maintaining a strict gluten free diet?”); scores range from 1-7, 
and higher scores indicate a higher perception of control over managing the GFD.  
 
Statistical analyses  
 All analyses were conducted using the Statistical Package for the Social Sciences (SPSS 
18.0). Correlations and t-tests were used to examine the relationships between QOL and the 
continuous and categorical variables respectively. Based on the CD data collected, several 
indices indicative of gastrointestinal symptoms were analysed including past and current 
symptom severity, reason for diagnosis, time to improvement after initiation of the GFD, and 
additional dietary intolerances and medical comorbidities. A hierarchical regression analysis 
predicting QOL was conducted, whereby the variables that showed significant relationships with 
QOL in the univariate analyses were entered as independent variables in three steps: 1) disease 
characteristics; 2) adherence variables (actual adherence and perceived difficulty); and 3) 
psychological and coping variables. Gender was controlled for due to gender differences 
observed on several of the disease and psychological variables. All analyses were two-tailed with 
a significance level of α = 0.05.  
STUDY 1 RESULTS 
Sample characteristics  
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 Three hundred and ninety individuals completed the survey (response rate = 13%; mean 
age = 44.2; SD = 12.7; 82.8% female). Most participants were either married or living with a 
partner (76%), and were engaged in full time or part time/casual work (74%), with a small 
number being unemployed, retired, or students. Overall the sample was well educated, with 74% 
having completed education beyond year 12. Table 1 shows a summary of the sample 
characteristics, and the relationships with QOL.  
 The mean QOL score was comparable to the average Australian population norms (47). 
The mean scores on each of the psychological symptom measures fell within the normal ranges 
(49-51). The mean adherence score fell in the excellent or very good range (52.7% excellent or 
very good; 36.4% moderate; 6.8% fair to poor) (52). The mean score for perceived difficulty 
indicated predominantly positive perceptions about the ability to manage the GFD (29).  
INSERT TABLE 1 HERE 
Demographic and disease factors 
 Poorer QOL was significantly associated with a greater number and longer duration of CD 
symptoms prior to diagnosis, and a longer time to improvement after initiation of the GFD (see 
Table 1). Participants who reported suffering from additional dietary intolerances (M = 4.00; SD 
= 0.87) had poorer QOL than those who did not (M = 4.34; SD = 0.72). Screen-detected patients 
(M = 4.39, SD = 0.72) had better QOL than symptom-detected patients (M = 4.21, SD = 0.79), 
and post-hoc analyses indicated this difference was mediated by the higher number of symptoms 
reported by the symptom-detected group (symptom-detected: M = 6.32, SD = 2.27; screen-
detected: M = 4.74, SD = 2.59; t = 5.79, p < .001; Sobel statistic = 3.42, p < .001). There were no 
gender differences in QOL, although females reported a greater number of symptoms (females: 
M = 6.15, SD = 2.41; males: M = 4.82, SD = 2.41, t = -4.01, p < .001) and more severe 
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recurrence of symptoms when consuming gluten since diagnosis than males (χ = 12.79, p < .05). 
Adherence and QOL were significantly related, as were the perceived level of difficulty 
associated with maintaining a strict GFD and QOL.  
Psychological symptoms and coping 
 Reduced QOL was significantly associated with higher levels of psychological symptoms 
and greater reliance on maladaptive coping (increased emotion-oriented and decreased task-
oriented; see Table 1). More severe gastrointestinal symptoms at diagnosis were also associated 
with increased depression (r = 0.18, p < .01), anxiety (r = 0.29, p < .001), stress (r = 0.28, p < 
.001), eating disorder risk (r = 0.15, p < .01), and emotion-oriented coping (r = 0.17, p < .01), but 
not with task-oriented coping (p > .05).   
Predicting QOL 
Gender and the disease characteristics accounted for 13.1% of the variance in QOL, 
although only the number of symptoms, time to improvement, and additional intolerances made 
significant independent contributions. Adherence and perceived difficulty added 14.3%, with 
adherence but not difficulty making an independent contribution. The addition of psychological 
symptoms and coping at step 3 brought the total variance accounted for to 44.5% (+17%), 
although only depression had a significant independent effect. The effects of number of 
symptoms, additional intolerances, time to improvement, and GFD adherence remained 
significant (see Table 2).  
INSERT TABLE 2 HERE 
STUDY 1 DISCUSSION 
As predicted, reduced QOL was related to heightened levels of psychological symptoms 
and maladaptive coping, poorer GFD adherence, and past (but not current) gastrointestinal 
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symptom severity. Longer duration of symptoms, longer time to improvement after initiation of 
the GFD, and the presence of additional dietary intolerances were also related to poorer QOL. 
Contrary to predictions, and inconsistent with previous research in CD (15, 19, 21) and across a 
wide variety of health conditions (53, 54), no gender differences in QOL were observed. 
Although the uneven gender distribution in this study is consistent with both the gender 
distribution of CD diagnoses (3) and the gender breakdown of the Coeliac Society’s database 
(55), it is possible that the predominance of females may have obscured potential differences. 
Alternatively, gender differences in QOL may not be as prevalent in CD sufferers in Australia.     
Consistent with the hypotheses, psychological factors and adherence were more strongly 
related to reduced QOL in individuals with CD than gastrointestinal symptoms. Further, although 
heightened symptom severity was indeed predictive of poorer QOL, the effect was reduced when 
GFD adherence and psychological symptoms were included. The relationship between 
heightened psychological symptoms and more severe gastrointestinal symptoms was also 
confirmed. This pattern of relationships has been reported in other illness populations (43, 44) 
but this study is the first to demonstrate such a link in CD. As was suggested by previous 
researchers (43, 44), it is possible that the presence of psychological symptoms, even at 
subclinical levels, resulted in the increased salience and subsequent reporting of gastrointestinal 
symptoms. These results also extend previous findings (24) by demonstrating that in addition to 
affecting physical and psychological QOL respectively, gastrointestinal and psychological 
symptoms both have negative impacts, albeit of differing strength, on overall QOL.  
The findings regarding coping were consistent with previous research (37), whereby the 
increased use of emotion-oriented coping was more strongly related to reduced QOL than the 
decreased use of task-oriented coping. The observation that coping was not predictive of QOL 
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after controlling for psychological symptoms also parallels previous findings in GFD adherence 
(46). It may be the case that coping plays a role in the development of psychological symptoms 
and ability to manage the GFD, as well as the perception of gastrointestinal symptoms, which in 
turn directly impact QOL. It has been suggested that difficulty in following the GFD rather than 
actual adherence exerts a negative impact on QOL (28). In contrast, here it was found that actual 
adherence to the GFD had a far greater negative impact on QOL than did the perceived level of 
difficulty; supporting the assertion that inadequate adherence does play an important role in QOL 
for individuals with CD.  
 A limitation of this study was the reliance on the number of symptoms experienced prior to 
diagnosis as a proxy measure for gastrointestinal symptom severity. While symptom severity at 
diagnosis using this type of measure has been linked to reduced QOL (18), current symptom 
severity probably represents a better predictor of QOL, as well as having the advantage of 
potentially being modifiable for intervention purposes. Here the measure of current symptom 
severity was specific to symptoms experienced when consuming gluten post GFD onset, and was 
not related to QOL. There are, however, a proportion of people who experience refractory CD; 
that is, the persistence of clinical symptoms despite being adherent to a strict GFD (56-58). 
Indeed, a recent study found a strong link between refractory CD and reduced QOL (59), 
suggesting that current symptom severity generally, rather than specific to gluten consumption, is 
likely to offer more insight into the relationship between gastrointestinal symptoms and QOL. 
Additional limitations will be discussed in the context of the general discussion.   
STUDY 2 AIMS AND HYPOTHESES 
Derived from the limitations of study 1, the primary aim of study 2 was to confirm the 
differential relationships between gastrointestinal symptoms, QOL, and psychological symptoms 
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by using a more reliable and well-validated measure of current symptom severity. It was 
hypothesised that while increased gastrointestinal symptoms, poorer GFD adherence, increased 
psychological symptoms, and reliance on maladaptive coping would predict reduced QOL, 
psychological symptoms would be more strongly related to QOL than gastrointestinal symptoms, 
and that the relationship between psychological symptoms and QOL would persist when 
controlling for gastrointestinal symptoms.   
STUDY 2 METHOD 
Participants and procedure 
 Participants were the baseline sample recruited to an online intervention to improve GFD 
adherence, coping, and QOL in CD (60). The recruitment strategy (email sent to 1500 members; 
April 2012), inclusion criteria, most measures, and procedure in this study were identical to 
study one. A description of the intervention content, procedure, and the trial outcome have been 
reported elsewhere (60); however, as in study 1 it was beyond the scope of that paper to examine 
the predictors of reduced QOL. For the purposes of the current analyses the baseline intervention 
sample was analysed cross-sectionally.   
Additional measures and analyses 
The Coeliac Disease Questionnaire (CDQ) – Gastrointestinal Symptoms subscale (61) 
provided a validated measure of current symptom severity, replacing the previous questions 
regarding the number and severity of symptoms experienced. The gastrointestinal symptoms 
subscale has seven items; scores range from 0-49, and higher scores indicate fewer/less severe 
gastrointestinal symptoms.  
In addition, the Brief COPE (62) replaced the Coping Inventory of Stressful Situations 
(51). This decision was based on the observation that coping did not add significantly to the 
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prediction of QOL (study 1) or GFD adherence (46) once psychological symptoms were 
included in the model, with the hope that a more comprehensive measure of the coping strategies 
employed by people with CD rather than the simple division into task-oriented and emotion-
oriented coping may further elucidate the role of coping in QOL. The scale contains 28 items 
measuring 14 distinct coping strategies; subscale scores range from 2-8, and higher scores 
indicate more frequent use of the coping strategy. Participants were asked to rate each coping 
strategy specifically according to how frequently they used it in relation to managing the 
challenges associated with the GFD. The statistical analyses conducted in study one were 
repeated here.  
STUDY 2 RESULTS 
Sample characteristics  
 One hundred and eighty-nine individuals completed the baseline survey (response rate = 
12.6%; mean age = 46.5, SD = 14.7; 87.3% female). Table 3 shows a summary of the sample 
characteristics and their relationships to QOL. The mean gastrointestinal symptom score was 
high indicating low severity of current symptoms (61). Regarding coping, the adaptive strategies 
(e.g., acceptance, active coping, planning,) were all used more frequently than the maladaptive 
ones (e.g., self-distraction, denial, self-blame,), and only the maladaptive strategies (plus seeking 
emotional support) were related to QOL.  
INSERT TABLE 3 HERE 
Predicting QOL 
Gender and current symptom severity accounted for 3.6% of the variance in QOL, 
although only symptoms made an independent contribution (see Table 4). Adherence and 
perceived difficulty contributed a further 7.7%, with adherence but not difficulty being 
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significant, and the effect of symptoms being reduced to non-significance. The addition of 
psychological symptoms added 23.8% to the model (total = 35.2%), with depression reducing 
the effects of both gastrointestinal symptoms and adherence to non-significance. Coping did not 
add to the prediction over and above psychological symptoms (p > .05; not shown).  
INSERT TABLE 4 HERE 
STUDY 2 DISCUSSION 
 This study confirmed the significant correlations observed in study one between reduced 
QOL and improved GFD adherence, heightened psychological symptoms and maladaptive 
coping, and increased gastrointestinal symptom severity, as well as between more severe 
gastrointestinal and psychological symptoms. Also consistent with study one was the differential 
magnitude of the relationships, with psychological symptoms again being more strongly related 
to reduced QOL than gastrointestinal symptom severity or the perceived difficulty associated 
with following a GFD.  
 The finding that depression had the strongest, and in fact only independent, relationship 
with reduced QOL is consistent with previous research across a wide range of populations (38). 
The results demonstrate that psychological factors are an important consideration, over and 
above the impact of gastrointestinal symptoms when investigating QOL in individuals with CD. 
The significant relations observed between gastrointestinal symptoms and psychological 
symptoms also support the suggestion that the presence of psychological symptoms may serve to 
intensify the perception of gastrointestinal symptoms, which together negatively impact QOL.  
 Also consistent with study one and previous research (37), the increased use of 
maladaptive coping strategies was more strongly related to decreased QOL than the reduced use 
of adaptive or task-oriented strategies, although not significantly so over and above the influence 
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of depression. That is, individuals who relied on distracting themselves from the difficult 
situation, denying the problem, or engaging in frequent self-blame in order to cope with the 
challenges of the GFD tended to have poorer QOL and higher levels of psychological symptoms. 
This was despite the finding that all of the adaptive strategies were used more frequently than the 
maladaptive strategies, and suggesting that interventions to improve QOL (and adherence) 
should focus explicitly on decreasing reliance on maladaptive strategies rather than merely 
boosting adaptive strategies, which most individuals with CD already seem to utilise.   
 In contrast to study one, the relationships between QOL and increased symptom duration 
and time to improvement, the presence of additional intolerances, and the reason for diagnosis 
(symptom-detected versus screen-detected) were not confirmed. One possible explanation for 
this is that participants who consented to participate in the second study (which subsequently 
involved completing a six-week intervention) may have been more invested in their health at 
baseline than the sample who were recruited for the simpler questionnaire study, with the former 
group having worked to overcome the potential negative impact of such disease characteristics 
on QOL.  
 Interestingly, the amount of variance in QOL accounted for by the CDQ was less than 
that accounted for by the number of symptoms experienced prior to diagnosis in study one. 
Despite this, the size of the correlations between gastrointestinal symptoms and psychological 
symptoms were similar across the two studies. Given that the participants in study two had 
relatively few/low severity symptoms at the time of assessment it is likely that symptoms had a 
lesser impact on QOL than the more severe symptoms experienced prior to diagnosis. Therefore 
in addition to the idea that psychological symptoms serve to exacerbate the perception of 
gastrointestinal symptoms, it may also be the case that symptoms prior to diagnosis have a 
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lasting negative impact on QOL via social and psychological functioning, which reduces as the 
incidence of such symptoms decreases. In both studies, however, the severity of gastrointestinal 
symptoms accounted for only a small amount of the variance in QOL, suggesting that the 
reductions in QOL seen in this population are the result of other factors – most notably 
psychological symptoms.   
GENERAL CONCLUSIONS AND LIMITATIONS 
Several limitations should be considered when interpreting these results. Firstly, 
recruitment via the Coeliac Society and the low response rates may have led to a self-selection 
bias, whereby members, and specifically those who chose to respond, may be more invested in 
their health and diet than the general CD population. This has been noted in other adherence 
studies (e.g., 21, 63); nonetheless, since it was relationships between the variables that were of 
interest, there is no reason to believe that these relationships would differ in a more or less 
satisfied/ adherent sample. 
Secondly, the use of self-report measures of psychological symptoms also represents a 
limitation, as high scores do not necessarily indicate a diagnosable condition. Regarding 
adherence, although the use of a concurrent dietitian rated assessment would strengthen the 
findings, the use of the well-validated CDAT means the current results can be viewed with more 
confidence than previous research which has relied on simple measures (e.g., Likert and visual 
analogue scales) that do not correspond with more objective measures (64). Finally, the cross-
sectional design means that the direction of causation between gastrointestinal and psychological 
symptoms, coping, adherence, and QOL is unclear. A longitudinal study is needed to confirm the 
complex and likely bidirectional relationships between these variables.  
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Notwithstanding these limitations this research is the first to investigate the combined 
impact of disease, psychological, and adherence factors on QOL in CD. It demonstrates that the 
presence of psychological symptoms (in particular depression) and an increased reliance on 
maladaptive coping strategies represent greater threats to achieving adequate QOL for 
individuals with CD than gastrointestinal symptoms. These results mirror those found in other 
disease populations (38), and highlight the importance of targeting both adherence to the GFD 
and psychological symptoms and coping in people with CD to minimise symptoms and 
maximise QOL outcomes, as has recently been demonstrated by the effectiveness of such an 
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Table 1. Disease, psychological, and adherence characteristics of the study 1 sample  
 Mean (SD) Range Relation to QOL (r) 
Age (years) 44.2 (12.7) 18 – 69  0.03 
Age at diagnosis (years) 37.4 (12.8) 1 – 64  0.03 
GFD duration (years) 6.8 (7.2) 0.25 – 48  -0.03 
Symptom duration (years) 9.9 (12.5) 0 – 60  -0.15** 
Number of symptoms  5.92 (2.46) 0 – 11  -0.22*** 
 Category % of sample Relation to QOL 
(t or ρ) 
Gender Female 82.8 0.84 
 Male 17.2  
Prompted diagnosis Symptoms 74.4 -2.01* 
 Screening 25.6  
No symptoms 5.1 0.01 
Mild 15.9  
Symptom recurrence  
Moderate  28.2  
 Severe 30.3  
 No gluten 20.5  
Time to improvement Less than 1 week 13.8 -0.14** 
 Less than 1 month  33.3  
 Up to 6 months 37.2  
 More than 6 months 11.0  
 No improvement 4.6  
Family history of CD  27.2 0.56 
Additional dietary intolerances  24.6 3.81*** 
Comorbid medical conditions  32.8 1.51 
 Mean (SD) Range  Relation to QOL (r) 
QOL 4.26 (0.77) 1 – 5  -  
Depression 6.20 (8.18) 0 – 42  -0.56*** 
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Anxiety 4.98 (6.16) 0 – 36  -0.43*** 
Stress 10.96 (9.29) 0 – 40  -0.46*** 
Eating disorder risk 27.27 (19.19) 0 – 91  -0.34*** 
Task-oriented coping 25.95 (4.89) 9 – 35  0.14** 
Emotion-oriented coping 19.17 (6.40) 7 – 35  -0.37*** 
GFD adherence 12.31 (3.17) 7 – 31 -0.41*** 
Perceived difficulty 6.41 (0.75)  2.25 – 7  0.17** 
Note: QOL = quality of life; SD = standard deviation; GFD = gluten free diet; CD = coeliac 
disease; * p < .05; ** p < .01; *** p < .001 
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Table 2. Summary of hierarchical regression analyses predicting QOL in study 1 
Variable  B β R2 F 
Step 1     
Gender 0.90 0.04   
Number of symptoms -0.75 -0.24***   
Symptom duration -0.00 -0.06   
Time to improvement -0.18 -0.24***   
Additional intolerances -0.24 -0.13*   
Prompted diagnosis -0.8 0.05 .131 8.60*** 
Step 2     
Gender 0.12 0.06   
Number of symptoms -0.06 -0.20***   
Symptom duration -0.00 -0.06   
Time to improvement -0.12 -0.15**   
Additional intolerances -0.25 -0.14**   
Prompted diagnosis 0.14 0.80   
GFD adherence -0.09 -0.37***   
Perceived difficulty 0.05 0.05 .275 16.05*** 
Step 3     
Gender 0.13 0.06   
Number of symptoms -0.04 -0.12*   
Symptom duration -0.00 -0.05   
Time to improvement -0.13 -0.18***   
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Additional intolerances -0.19 -0.11*   
Prompted diagnosis 0.12 0.07   
GFD adherence -0.05 -0.22***   
Perceived difficulty -0.01 -0.01   
Depression -0.04 -0.38***   
Anxiety -0.01 -0.05   
Stress 0.00 0.00   
Eating disorder risk -0.00 -0.06   
Task-oriented coping 0.00 -0.00   
Emotion-oriented coping -0.00 -0.03 .445 19.06*** 




Table 3. Disease, psychological, and adherence characteristics of the study 2 sample  
 Mean (SD) Range Relation to QOL 
(r) 
Age at diagnosis (years) 42.1 (14.5) 1 – 73  0.03 
GFD duration (years) 4.6 (7.0) 0.25 – 50 0.10 
Symptom duration (years) 9.1 (13.2) 0 – 60  -0.12 
 Category % of sample Relation to QOL 
(t or ρ) 
Gender Female 87.3 -0.77 
 Male 12.6  
Prompted diagnosis Symptoms 79.9 -0.17 
 Screening 21.1  
Time to improvement Less than 1 week  0.03 
 Less than 1 month    
 Up to 6 months   
 More than 6 months   
 No improvement   
Family history of CD  24.3  
Additional dietary intolerances  33.9 -0.30 
Comorbid medical conditions  35.4 -1.95 
 Mean (SD) Range  Relation to QOL 
(r) 
QOL 4.24 (0.81) 1 – 5  -  
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Depression ^ 5.94 (7.39) 0 – 42  -0.57*** 
Anxiety ^ 4.72 (5.97) 0 – 32  -0.30*** 
Stress ^ 9.35 (8.32) 0 – 40  -0.41*** 
Eating disorder risk ^ 29.70 (20.48) 0 – 86  -0.11 
Active 5.52 (1.87) 2 – 8  -0.11 
Emotional support 4.39 (1.84) 2 – 8  0.14* 
Instrumental support 4.38 (1.81) 2 – 8  0.02 
Positive reframing 4.68 (1.82) 2 – 8  -0.04 
Planning 4.99 (1.81) 2 – 8  -0.06 
Acceptance 6.72 (1.51)  2 – 8  0.11 
Self-distraction ^ 3.29 (1.52) 2 – 8 -0.40*** 
Denial 2.34 (0.87) 2 – 8  -0.18* 
Substance use ^ 2.51 (1.04) 2 – 6  0.00 
Behavioural disengagement 2.26 (0.68) 2 – 7  -0.21** 
Venting ^ 3.26 (1.20) 2 – 8  -0.14 
Self-blame ^ 2.83 (1.29) 2 – 8  -0.26*** 
Humour 3.64 (1.66)  2 – 8  0.03 
Religion  2.87 (1.60) 2 – 8  -0.00 
GFD adherence 12.20 (3.44) 7 – 28 -0.32*** 
Perceived difficulty 6.37 (0.84)  1.50 – 7  0.19** 
Gastrointestinal symptoms # 39.24 (7.03) 18 – 49  0.17* 
Note: QOL = quality of life; SD = standard deviation; GFD = gluten free diet; * p < .05; ** p < 
.01; *** p < .001; the mean QOL score was comparable to the average Australian population 
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norms (M = 4.3; SD = 0.8); scores for depression, anxiety, stress, and eating disorder risk fell in 
the normal/average ranges; mean adherence score is in the excellent or very good range (59.3% 
excellent or very good; 32.8% moderate; 7.9% fair-to-poor); ^ Significant correlations with 
gastrointestinal symptoms (depression: r = -0.19, p < .01; anxiety: r = -0.21, p < .01; stress: r = -
0.22, p < .01; eating disorder risk: r = -0.18, p < .01; self-distraction: r = -0.22, p < .01; 
substance use: r = -0.20, p < .01; self-blame: r = -0.18, p < .05);  # Females (M = 38.8; SD = 7.1) 
reported more severe gastrointestinal symptoms than males (M = 42.1; SD = 5.7; t = 2.18, p < 
.05).  
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Table 4. Summary of hierarchical regression analyses predicting QOL in study 2 
Variable  B β R2 F 
Step 1     
Gender 0.21 0.09   
Gastrointestinal symptoms 0.02 0.18* 0.036 3.48*** 
Step 2     
Gender 0.23 0.10   
Gastrointestinal symptoms 0.01 0.09   
GFD adherence -0.07 -0.28**   
Perceived difficulty 0.03 0.03 0.113 5.87*** 
Step 3     
Gender 0.15 0.06   
Gastrointestinal symptoms 0.01 0.07   
GFD adherence -0.02 -0.07   
Perceived difficulty 0.02 0.02   
Depression -0.06 -0.56***   
Anxiety 0.01 0.04   
Stress -0.01 -0.06   
Eating disorder risk 0.01 0.14 0.352 12.20*** 
Note: QOL = quality of life; GFD = gluten free diet; * p < .05; ** p < .01; *** p < .001
